Table 4

ORs (95% CIs) of invasive breast cancer according to cohort-specific quartiles of estrone metabolite or metabolite ratio, postmenopausal women, the NYUWHS and the NSMSC cohorts (499 cases, 499 controls)

OR (95% CI)
Estrone metaboliteQuartile 1Quartile 2Quartile 3Quartile 4P trend
All subjects
 2-OHE1, pg/mL
  Cases/controls120/126129/125102/125148/123
  Unadjusteda1.001.12 (0.77–1.62)0.87 (0.59–1.30)1.34 (0.90–1.99)0.29
  Adjusted for estroneb1.001.07 (0.73–1.55)0.80 (0.54–1.21)1.04 (0.68–1.58)0.80
  Multivariate-adjustedc1.001.04 (0.71–1.53)0.78 (0.52–1.18)0.98 (0.64–1.51)0.63
 16α-OHE1, pg/mL
  Cases/controls115/126114/125158/124112/124
  Unadjusteda1.001.01 (0.69–1.48)1.42 (0.99–2.04)1.02 (0.71–1.47)0.53
  Adjusted for estroneb1.000.95 (0.64–1.40)1.24 (0.85–1.80)0.81 (0.55–1.19)0.52
  Multivariate-adjustedc1.000.94 (0.63–1.40)1.30 (0.88–1.90)0.81 (0.54–1.20)0.60
 2-OHE1:16α-OHE1 ratio
  Cases/controls127/129119/121105/125148/124
  Unadjusteda1.000.99 (0.69–1.42)0.86 (0.59–1.26)1.32 (0.88–1.97)0.33
  Adjusted for estroneb1.001.01 (0.70–1.46)0.83 (0.56–1.22)1.17 (0.77–1.77)0.75
  Multivariate-adjustedc1.001.02 (0.70–1.48)0.82 (0.55–1.22)1.13 (0.74–1.73)0.88
NYUWHS
 2-OHE1, pg/mL
  Cases/controls93/9084/9073/90108/88
  Unadjusteda1.000.93 (0.59–1.44)0.78 (0.49–1.25)1.21 (0.77–1.91)0.46
  Adjusted for estroneb1.000.90 (0.57–1.42)0.72 (0.45–1.16)0.88 (0.54–1.44)0.47
  Multivariate-adjustedc1.000.88 (0.55–1.40)0.72 (0.44–1.17)0.84 (0.51–1.37)0.38
 16α-OHE1, pg/mL
  Cases/controls86/9084/89106/9082/89
  Unadjusteda1.001.00 (0.64–1.55)1.24 (0.81–1.90)0.98 (0.64–1.51)0.84
  Adjusted for estroneb1.000.91 (0.58–1.44)1.03 (0.66–1.60)0.74 (0.47–1.16)0.27
  Multivariate-adjustedc1.000.87 (0.54–1.40)1.03 (0.65–1.63)0.72 (0.45–1.15)0.26
 2-OHE1:16α-OHE1 ratio
  Cases/controls98/9377/8674/90109/89
  Unadjusteda1.000.85 (0.55–1.30)0.79 (0.50–1.25)1.31 (0.80–2.15)0.45
  Adjusted for estroneb1.000.86 (0.56–1.33)0.74 (0.46–1.19)1.13 (0.68–1.88)0.90
  Multivariate-adjustedc1.000.88 (0.57–1.37)0.74 (0.46–1.21)1.11 (0.66–1.89)0.96
NSMSC
 2-OHE1, pg/mL
  Cases/controls27/3645/3529/3540/35
  Unadjusteda1.001.78 (0.88–3.60)1.23 (0.57–2.65)1.78 (0.77–4.08)0.40
  Adjusted for estroneb1.001.65 (0.81–3.36)1.14 (0.52–2.49)1.54 (0.65–3.63)0.62
  Multivariate-adjustedc1.001.48 (0.68–3.20)0.86 (0.37–2.02)1.28 (0.51–3.24)0.99
 16α-OHE1, pg/mL
  Cases/controls29/3630/3652/3430/35
  Unadjusteda1.001.00 (0.47–2.13)1.99 (0.99–3.98)1.12 (0.54–2.34)0.38
  Adjusted for estroneb1.000.98 (0.45–2.13)1.87 (0.92–3.80)0.95 (0.44–2.05)0.64
  Multivariate-adjustedc1.001.04 (0.46–2.35)1.87 (0.88–3.99)0.88 (0.38–2.00)0.82
 2-OHE1:16α-OHE1 ratio
  Cases/controls29/3642/3531/3539/35
  Unadjusteda1.001.51 (0.75–3.03)1.17 (0.58–2.36)1.43 (0.70–2.91)0.54
  Adjusted for estroneb1.001.54 (0.76–3.12)1.14 (0.56–2.32)1.32 (0.64–2.74)0.74
  Multivariate-adjustedc1.001.67 (0.78–3.57)1.06 (0.49–2.29)1.39 (0.62–3.13)0.83
  • aConditional logistic regression (matching variables: age, date of blood donation, and cohort).

  • bConditional logistic regression adjusting for log-transformed estrone levels.

  • cConditional logistic regression adjusting for log-transformed estrone levels, log-transformed BMI, height (continuous), age at menarche (continuous), age at menopause (continuous), family history of breast cancer (negative, positive), age at first birth/parity (≤20, 21–25, 26–30, >30 years, or nulliparous), oral contraceptive use (never, ever), HRT use (never, ever), and complete oophorectomy (no, yes).